Clinical Trial Education, Treatment Access Central to Improving Lung Cancer Care: Deborah Doroshow, MD, PhD

Why It Matters

Without widespread trial awareness and equitable access, life‑extending lung‑cancer therapies cannot reach the patients who need them, limiting survival gains and slowing innovation.

Key Takeaways

• Early trial education integrates studies into standard lung‑cancer care
• KRAS G12D inhibitors expand targeted‑therapy options beyond G12C
• Antibody‑drug conjugate trials outpace feasible study designs
• Insurance, immigration, travel delays hinder timely treatment access
• Equitable access is prerequisite for realizing oncology breakthroughs

Pulse Analysis

Lung cancer remains the leading cause of cancer death in the United States, accounting for roughly 25% of all cancer fatalities. Because the disease is often diagnosed at an advanced stage, clinical trials serve as a critical pathway to novel therapies that can improve survival. Yet patient awareness of trial options is surprisingly low, even among those with medical backgrounds. Early education—introducing the concept at diagnosis rather than as a last resort—has been shown to increase enrollment rates and diversify study populations, thereby enhancing the generalizability of trial results.

The therapeutic landscape is shifting dramatically thanks to precision medicine. KRAS mutations, once deemed undruggable, now have multiple inhibitors targeting both G12C and the emerging G12D variants, expanding options for a sizable subset of lung‑cancer patients. Simultaneously, antibody‑drug conjugates (ADCs) are proliferating, delivering cytotoxic payloads directly to tumor cells while sparing healthy tissue. However, the sheer volume of ADC trials exceeds the capacity of traditional study designs, prompting calls for adaptive protocols and biomarker‑driven enrollment strategies to ensure efficient evaluation and rapid patient access.

Despite scientific advances, systemic barriers continue to impede treatment delivery. Insurance denials, shifting eligibility criteria, immigration status, and the geographic concentration of specialty centers can delay therapy by months, eroding potential benefits. Policymakers and health systems must prioritize patient navigation services, tele‑medicine outreach, and value‑based insurance models that align coverage with emerging standards of care. Only by removing these access obstacles can the oncology community fully capitalize on breakthrough therapies and deliver equitable outcomes for all lung‑cancer patients.